Loading…

Guidelines, “minimal requirements” and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working party

Abstract Glioblastoma is the most common and the most lethal primary brain tumor in adults. Although studies are ongoing, the epidemiology of glioblastoma in North Africa ( i.e. Morocco, Algeria and Tunisia) remains imperfectly settled and needs to be specified for a better optimization of the neuro...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2016-02, Vol.98, p.189-199
Main Authors: Belkacemi, Y., Bolle, S., Bourdeaut, F., Collin, P., Cornu, P., Delatre, J.-Y., Dhermain, F., Doz, F., Habrand, J.-L., Hoang-Xuan, K., Idbaih, A., Mammar, H., Martin-Duverneuil, N., Mokhtari, K., Roujeau, T., Acharqui, A., Atit Benali, S., Bakhti, S., Bena, F., Bendjaafar, N., Benider, A., Bouaouina, N., Bounedjar, A., Boussen, H., Bouyoucef, K., Bouzid, K., Chougai, Z., Daoud, J., Errihani, H., Essoudaigui, F., Gachi, F., Harif, M., Hilmani, S., Hsissen, L., Idali, B., Karkouri, M., Kerboua, E., Ouahabi, A., Sahraoui, S., Sadki, O., Sami, A., Samlali, R, Terkmani, F.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c499t-3fb24d3333df976ab90a53e568c0660fe6df0b05255065c27aab2d3b7be4c8af3
cites cdi_FETCH-LOGICAL-c499t-3fb24d3333df976ab90a53e568c0660fe6df0b05255065c27aab2d3b7be4c8af3
container_end_page 199
container_issue
container_start_page 189
container_title Critical reviews in oncology/hematology
container_volume 98
creator Belkacemi, Y.
Bolle, S.
Bourdeaut, F.
Collin, P.
Cornu, P.
Delatre, J.-Y.
Dhermain, F.
Doz, F.
Habrand, J.-L.
Hoang-Xuan, K.
Idbaih, A.
Mammar, H.
Martin-Duverneuil, N.
Mokhtari, K.
Roujeau, T.
Acharqui, A.
Atit Benali, S.
Bakhti, S.
Bena, F.
Bendjaafar, N.
Benider, A.
Bouaouina, N.
Bounedjar, A.
Boussen, H.
Bouyoucef, K.
Bouzid, K.
Chougai, Z.
Daoud, J.
Errihani, H.
Essoudaigui, F.
Gachi, F.
Harif, M.
Hilmani, S.
Hsissen, L.
Idali, B.
Karkouri, M.
Kerboua, E.
Ouahabi, A.
Sahraoui, S.
Sadki, O.
Sami, A.
Samlali, R
Terkmani, F.
description Abstract Glioblastoma is the most common and the most lethal primary brain tumor in adults. Although studies are ongoing, the epidemiology of glioblastoma in North Africa ( i.e. Morocco, Algeria and Tunisia) remains imperfectly settled and needs to be specified for a better optimization of the neuro-oncology healthcare across the Mediterranean area and in North Africa countries. Over the last years significant therapeutic advances have been accomplished improving survival and quality of life of glioblastoma patients. Indeed, concurrent temozolomide-radiotherapy (temoradiation) and adjuvant temozolomide has been established as the standard of care associated with a survival benefit and a better outcome. Therefore, considering this validated strategy and regarding the means and some other North Africa countries specificities, we decided, under the auspices of AROME (association of radiotherapy and oncology of the Mediterranean area; www.aromecancer.org ), a non-profit organization, to organize a dedicated meeting to discuss the standards and elaborate a consensus on the “minimal requirements” adapted to the local resources. Thus, panels of physicians involved in daily multidisciplinary brain tumors management in the two borders of the Mediterranean area have been invited to the AROME neuro-oncology working party. We report here the consensus, established for minimal human and material resources for glioblastoma diagnosis and treatment faced to the standard of care, which should be reached. If the minimal requirements are not reached, the patients should be referred to the closest specialized medical center where at least minimal requirements, or, ideally, the standard of care should be guaranteed to the patients.
doi_str_mv 10.1016/j.critrevonc.2015.10.014
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1760924434</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1040842815300640</els_id><sourcerecordid>1760924434</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-3fb24d3333df976ab90a53e568c0660fe6df0b05255065c27aab2d3b7be4c8af3</originalsourceid><addsrcrecordid>eNqNksFu1DAQhiMEoqXwCsjHIpHFcRwn4YC0VNuC1LJSgbPlOJPF28Tejp2ivfVBystVPAhOtxQJLvhgW57P_9jzT5KQjM4ymok365lGExCunNUzRrMiHs9oxh8l-1lV1inlInsc95TTtOKs2kueeb-mlHIuyqfJHhOCCcbEfvLzZDQt9MaCf01ur28GY82geoJwORqEAWzwt9c_iLIt8SHOClviOqIVAjGWrHrjml754AZFFLoxcuEbkDNoTQBEZUFZMkdQb8k8qm4cBtKhG-6o-fnybEEO5947bVQwzk7a56o1LoZRbbZ3iZdWu96ttlPwX3GFC_WKfIIRXfpAfnd4YeyKbBSG7fPkSad6Dy_u14Pk6_Hiy9GH9HR58vFofppqXtchzbuG8TaPo-3qUqimpqrIoRCVpkLQDkTb0YYWrCioKDQrlWpYmzdlA1xXqssPksOd7gbd5Qg-yMF4DX0fH-pGL7NS0JpxnvOIVjtUo_MeoZMbjIXHrcyonDyWa_nHYzl5PEWix_Hqy_ssYzNA-3Dxt6kReL8DIP71ygBKrw1YHauGoINsnfmfLO_-EtGxS4xW_QVswa_diDbWUmbSM0nl56nXplbLipxSwWn-C7nh2TM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1760924434</pqid></control><display><type>article</type><title>Guidelines, “minimal requirements” and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working party</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Belkacemi, Y. ; Bolle, S. ; Bourdeaut, F. ; Collin, P. ; Cornu, P. ; Delatre, J.-Y. ; Dhermain, F. ; Doz, F. ; Habrand, J.-L. ; Hoang-Xuan, K. ; Idbaih, A. ; Mammar, H. ; Martin-Duverneuil, N. ; Mokhtari, K. ; Roujeau, T. ; Acharqui, A. ; Atit Benali, S. ; Bakhti, S. ; Bena, F. ; Bendjaafar, N. ; Benider, A. ; Bouaouina, N. ; Bounedjar, A. ; Boussen, H. ; Bouyoucef, K. ; Bouzid, K. ; Chougai, Z. ; Daoud, J. ; Errihani, H. ; Essoudaigui, F. ; Gachi, F. ; Harif, M. ; Hilmani, S. ; Hsissen, L. ; Idali, B. ; Karkouri, M. ; Kerboua, E. ; Ouahabi, A. ; Sahraoui, S. ; Sadki, O. ; Sami, A. ; Samlali, R ; Terkmani, F.</creator><creatorcontrib>Belkacemi, Y. ; Bolle, S. ; Bourdeaut, F. ; Collin, P. ; Cornu, P. ; Delatre, J.-Y. ; Dhermain, F. ; Doz, F. ; Habrand, J.-L. ; Hoang-Xuan, K. ; Idbaih, A. ; Mammar, H. ; Martin-Duverneuil, N. ; Mokhtari, K. ; Roujeau, T. ; Acharqui, A. ; Atit Benali, S. ; Bakhti, S. ; Bena, F. ; Bendjaafar, N. ; Benider, A. ; Bouaouina, N. ; Bounedjar, A. ; Boussen, H. ; Bouyoucef, K. ; Bouzid, K. ; Chougai, Z. ; Daoud, J. ; Errihani, H. ; Essoudaigui, F. ; Gachi, F. ; Harif, M. ; Hilmani, S. ; Hsissen, L. ; Idali, B. ; Karkouri, M. ; Kerboua, E. ; Ouahabi, A. ; Sahraoui, S. ; Sadki, O. ; Sami, A. ; Samlali, R ; Terkmani, F. ; French Panel by alphabetic order ; North Africa Panel by alphabetic order ; North Africa Panel ; French Panel</creatorcontrib><description>Abstract Glioblastoma is the most common and the most lethal primary brain tumor in adults. Although studies are ongoing, the epidemiology of glioblastoma in North Africa ( i.e. Morocco, Algeria and Tunisia) remains imperfectly settled and needs to be specified for a better optimization of the neuro-oncology healthcare across the Mediterranean area and in North Africa countries. Over the last years significant therapeutic advances have been accomplished improving survival and quality of life of glioblastoma patients. Indeed, concurrent temozolomide-radiotherapy (temoradiation) and adjuvant temozolomide has been established as the standard of care associated with a survival benefit and a better outcome. Therefore, considering this validated strategy and regarding the means and some other North Africa countries specificities, we decided, under the auspices of AROME (association of radiotherapy and oncology of the Mediterranean area; www.aromecancer.org ), a non-profit organization, to organize a dedicated meeting to discuss the standards and elaborate a consensus on the “minimal requirements” adapted to the local resources. Thus, panels of physicians involved in daily multidisciplinary brain tumors management in the two borders of the Mediterranean area have been invited to the AROME neuro-oncology working party. We report here the consensus, established for minimal human and material resources for glioblastoma diagnosis and treatment faced to the standard of care, which should be reached. If the minimal requirements are not reached, the patients should be referred to the closest specialized medical center where at least minimal requirements, or, ideally, the standard of care should be guaranteed to the patients.</description><identifier>ISSN: 1040-8428</identifier><identifier>EISSN: 1879-0461</identifier><identifier>DOI: 10.1016/j.critrevonc.2015.10.014</identifier><identifier>PMID: 26626226</identifier><language>eng</language><publisher>Netherlands: Elsevier Ireland Ltd</publisher><subject>Adult ; Africa, Northern ; AROME ; Brain Neoplasms - pathology ; Brain Neoplasms - therapy ; Brain tumors ; Dacarbazine - analogs &amp; derivatives ; Glioblastoma ; Glioblastoma - pathology ; Glioblastoma - therapy ; Guidelines for practice ; Hematology, Oncology and Palliative Medicine ; Humans ; Medical Oncology - organization &amp; administration ; Medical Oncology - standards ; Mediterranean Region ; Neurology - organization &amp; administration ; Neurology - standards ; Practice Guidelines as Topic ; Quality of Life ; Radiotherapy ; Radiotherapy - standards ; Societies, Medical - organization &amp; administration ; Societies, Medical - standards ; Standard of Care ; Temozolomide</subject><ispartof>Critical reviews in oncology/hematology, 2016-02, Vol.98, p.189-199</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2015 Elsevier Ireland Ltd</rights><rights>Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-3fb24d3333df976ab90a53e568c0660fe6df0b05255065c27aab2d3b7be4c8af3</citedby><cites>FETCH-LOGICAL-c499t-3fb24d3333df976ab90a53e568c0660fe6df0b05255065c27aab2d3b7be4c8af3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26626226$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Belkacemi, Y.</creatorcontrib><creatorcontrib>Bolle, S.</creatorcontrib><creatorcontrib>Bourdeaut, F.</creatorcontrib><creatorcontrib>Collin, P.</creatorcontrib><creatorcontrib>Cornu, P.</creatorcontrib><creatorcontrib>Delatre, J.-Y.</creatorcontrib><creatorcontrib>Dhermain, F.</creatorcontrib><creatorcontrib>Doz, F.</creatorcontrib><creatorcontrib>Habrand, J.-L.</creatorcontrib><creatorcontrib>Hoang-Xuan, K.</creatorcontrib><creatorcontrib>Idbaih, A.</creatorcontrib><creatorcontrib>Mammar, H.</creatorcontrib><creatorcontrib>Martin-Duverneuil, N.</creatorcontrib><creatorcontrib>Mokhtari, K.</creatorcontrib><creatorcontrib>Roujeau, T.</creatorcontrib><creatorcontrib>Acharqui, A.</creatorcontrib><creatorcontrib>Atit Benali, S.</creatorcontrib><creatorcontrib>Bakhti, S.</creatorcontrib><creatorcontrib>Bena, F.</creatorcontrib><creatorcontrib>Bendjaafar, N.</creatorcontrib><creatorcontrib>Benider, A.</creatorcontrib><creatorcontrib>Bouaouina, N.</creatorcontrib><creatorcontrib>Bounedjar, A.</creatorcontrib><creatorcontrib>Boussen, H.</creatorcontrib><creatorcontrib>Bouyoucef, K.</creatorcontrib><creatorcontrib>Bouzid, K.</creatorcontrib><creatorcontrib>Chougai, Z.</creatorcontrib><creatorcontrib>Daoud, J.</creatorcontrib><creatorcontrib>Errihani, H.</creatorcontrib><creatorcontrib>Essoudaigui, F.</creatorcontrib><creatorcontrib>Gachi, F.</creatorcontrib><creatorcontrib>Harif, M.</creatorcontrib><creatorcontrib>Hilmani, S.</creatorcontrib><creatorcontrib>Hsissen, L.</creatorcontrib><creatorcontrib>Idali, B.</creatorcontrib><creatorcontrib>Karkouri, M.</creatorcontrib><creatorcontrib>Kerboua, E.</creatorcontrib><creatorcontrib>Ouahabi, A.</creatorcontrib><creatorcontrib>Sahraoui, S.</creatorcontrib><creatorcontrib>Sadki, O.</creatorcontrib><creatorcontrib>Sami, A.</creatorcontrib><creatorcontrib>Samlali, R</creatorcontrib><creatorcontrib>Terkmani, F.</creatorcontrib><creatorcontrib>French Panel by alphabetic order</creatorcontrib><creatorcontrib>North Africa Panel by alphabetic order</creatorcontrib><creatorcontrib>North Africa Panel</creatorcontrib><creatorcontrib>French Panel</creatorcontrib><title>Guidelines, “minimal requirements” and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working party</title><title>Critical reviews in oncology/hematology</title><addtitle>Crit Rev Oncol Hematol</addtitle><description>Abstract Glioblastoma is the most common and the most lethal primary brain tumor in adults. Although studies are ongoing, the epidemiology of glioblastoma in North Africa ( i.e. Morocco, Algeria and Tunisia) remains imperfectly settled and needs to be specified for a better optimization of the neuro-oncology healthcare across the Mediterranean area and in North Africa countries. Over the last years significant therapeutic advances have been accomplished improving survival and quality of life of glioblastoma patients. Indeed, concurrent temozolomide-radiotherapy (temoradiation) and adjuvant temozolomide has been established as the standard of care associated with a survival benefit and a better outcome. Therefore, considering this validated strategy and regarding the means and some other North Africa countries specificities, we decided, under the auspices of AROME (association of radiotherapy and oncology of the Mediterranean area; www.aromecancer.org ), a non-profit organization, to organize a dedicated meeting to discuss the standards and elaborate a consensus on the “minimal requirements” adapted to the local resources. Thus, panels of physicians involved in daily multidisciplinary brain tumors management in the two borders of the Mediterranean area have been invited to the AROME neuro-oncology working party. We report here the consensus, established for minimal human and material resources for glioblastoma diagnosis and treatment faced to the standard of care, which should be reached. If the minimal requirements are not reached, the patients should be referred to the closest specialized medical center where at least minimal requirements, or, ideally, the standard of care should be guaranteed to the patients.</description><subject>Adult</subject><subject>Africa, Northern</subject><subject>AROME</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain Neoplasms - therapy</subject><subject>Brain tumors</subject><subject>Dacarbazine - analogs &amp; derivatives</subject><subject>Glioblastoma</subject><subject>Glioblastoma - pathology</subject><subject>Glioblastoma - therapy</subject><subject>Guidelines for practice</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Medical Oncology - organization &amp; administration</subject><subject>Medical Oncology - standards</subject><subject>Mediterranean Region</subject><subject>Neurology - organization &amp; administration</subject><subject>Neurology - standards</subject><subject>Practice Guidelines as Topic</subject><subject>Quality of Life</subject><subject>Radiotherapy</subject><subject>Radiotherapy - standards</subject><subject>Societies, Medical - organization &amp; administration</subject><subject>Societies, Medical - standards</subject><subject>Standard of Care</subject><subject>Temozolomide</subject><issn>1040-8428</issn><issn>1879-0461</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqNksFu1DAQhiMEoqXwCsjHIpHFcRwn4YC0VNuC1LJSgbPlOJPF28Tejp2ivfVBystVPAhOtxQJLvhgW57P_9jzT5KQjM4ymok365lGExCunNUzRrMiHs9oxh8l-1lV1inlInsc95TTtOKs2kueeb-mlHIuyqfJHhOCCcbEfvLzZDQt9MaCf01ur28GY82geoJwORqEAWzwt9c_iLIt8SHOClviOqIVAjGWrHrjml754AZFFLoxcuEbkDNoTQBEZUFZMkdQb8k8qm4cBtKhG-6o-fnybEEO5947bVQwzk7a56o1LoZRbbZ3iZdWu96ttlPwX3GFC_WKfIIRXfpAfnd4YeyKbBSG7fPkSad6Dy_u14Pk6_Hiy9GH9HR58vFofppqXtchzbuG8TaPo-3qUqimpqrIoRCVpkLQDkTb0YYWrCioKDQrlWpYmzdlA1xXqssPksOd7gbd5Qg-yMF4DX0fH-pGL7NS0JpxnvOIVjtUo_MeoZMbjIXHrcyonDyWa_nHYzl5PEWix_Hqy_ssYzNA-3Dxt6kReL8DIP71ygBKrw1YHauGoINsnfmfLO_-EtGxS4xW_QVswa_diDbWUmbSM0nl56nXplbLipxSwWn-C7nh2TM</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Belkacemi, Y.</creator><creator>Bolle, S.</creator><creator>Bourdeaut, F.</creator><creator>Collin, P.</creator><creator>Cornu, P.</creator><creator>Delatre, J.-Y.</creator><creator>Dhermain, F.</creator><creator>Doz, F.</creator><creator>Habrand, J.-L.</creator><creator>Hoang-Xuan, K.</creator><creator>Idbaih, A.</creator><creator>Mammar, H.</creator><creator>Martin-Duverneuil, N.</creator><creator>Mokhtari, K.</creator><creator>Roujeau, T.</creator><creator>Acharqui, A.</creator><creator>Atit Benali, S.</creator><creator>Bakhti, S.</creator><creator>Bena, F.</creator><creator>Bendjaafar, N.</creator><creator>Benider, A.</creator><creator>Bouaouina, N.</creator><creator>Bounedjar, A.</creator><creator>Boussen, H.</creator><creator>Bouyoucef, K.</creator><creator>Bouzid, K.</creator><creator>Chougai, Z.</creator><creator>Daoud, J.</creator><creator>Errihani, H.</creator><creator>Essoudaigui, F.</creator><creator>Gachi, F.</creator><creator>Harif, M.</creator><creator>Hilmani, S.</creator><creator>Hsissen, L.</creator><creator>Idali, B.</creator><creator>Karkouri, M.</creator><creator>Kerboua, E.</creator><creator>Ouahabi, A.</creator><creator>Sahraoui, S.</creator><creator>Sadki, O.</creator><creator>Sami, A.</creator><creator>Samlali, R</creator><creator>Terkmani, F.</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160201</creationdate><title>Guidelines, “minimal requirements” and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working party</title><author>Belkacemi, Y. ; Bolle, S. ; Bourdeaut, F. ; Collin, P. ; Cornu, P. ; Delatre, J.-Y. ; Dhermain, F. ; Doz, F. ; Habrand, J.-L. ; Hoang-Xuan, K. ; Idbaih, A. ; Mammar, H. ; Martin-Duverneuil, N. ; Mokhtari, K. ; Roujeau, T. ; Acharqui, A. ; Atit Benali, S. ; Bakhti, S. ; Bena, F. ; Bendjaafar, N. ; Benider, A. ; Bouaouina, N. ; Bounedjar, A. ; Boussen, H. ; Bouyoucef, K. ; Bouzid, K. ; Chougai, Z. ; Daoud, J. ; Errihani, H. ; Essoudaigui, F. ; Gachi, F. ; Harif, M. ; Hilmani, S. ; Hsissen, L. ; Idali, B. ; Karkouri, M. ; Kerboua, E. ; Ouahabi, A. ; Sahraoui, S. ; Sadki, O. ; Sami, A. ; Samlali, R ; Terkmani, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-3fb24d3333df976ab90a53e568c0660fe6df0b05255065c27aab2d3b7be4c8af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Africa, Northern</topic><topic>AROME</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain Neoplasms - therapy</topic><topic>Brain tumors</topic><topic>Dacarbazine - analogs &amp; derivatives</topic><topic>Glioblastoma</topic><topic>Glioblastoma - pathology</topic><topic>Glioblastoma - therapy</topic><topic>Guidelines for practice</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Medical Oncology - organization &amp; administration</topic><topic>Medical Oncology - standards</topic><topic>Mediterranean Region</topic><topic>Neurology - organization &amp; administration</topic><topic>Neurology - standards</topic><topic>Practice Guidelines as Topic</topic><topic>Quality of Life</topic><topic>Radiotherapy</topic><topic>Radiotherapy - standards</topic><topic>Societies, Medical - organization &amp; administration</topic><topic>Societies, Medical - standards</topic><topic>Standard of Care</topic><topic>Temozolomide</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Belkacemi, Y.</creatorcontrib><creatorcontrib>Bolle, S.</creatorcontrib><creatorcontrib>Bourdeaut, F.</creatorcontrib><creatorcontrib>Collin, P.</creatorcontrib><creatorcontrib>Cornu, P.</creatorcontrib><creatorcontrib>Delatre, J.-Y.</creatorcontrib><creatorcontrib>Dhermain, F.</creatorcontrib><creatorcontrib>Doz, F.</creatorcontrib><creatorcontrib>Habrand, J.-L.</creatorcontrib><creatorcontrib>Hoang-Xuan, K.</creatorcontrib><creatorcontrib>Idbaih, A.</creatorcontrib><creatorcontrib>Mammar, H.</creatorcontrib><creatorcontrib>Martin-Duverneuil, N.</creatorcontrib><creatorcontrib>Mokhtari, K.</creatorcontrib><creatorcontrib>Roujeau, T.</creatorcontrib><creatorcontrib>Acharqui, A.</creatorcontrib><creatorcontrib>Atit Benali, S.</creatorcontrib><creatorcontrib>Bakhti, S.</creatorcontrib><creatorcontrib>Bena, F.</creatorcontrib><creatorcontrib>Bendjaafar, N.</creatorcontrib><creatorcontrib>Benider, A.</creatorcontrib><creatorcontrib>Bouaouina, N.</creatorcontrib><creatorcontrib>Bounedjar, A.</creatorcontrib><creatorcontrib>Boussen, H.</creatorcontrib><creatorcontrib>Bouyoucef, K.</creatorcontrib><creatorcontrib>Bouzid, K.</creatorcontrib><creatorcontrib>Chougai, Z.</creatorcontrib><creatorcontrib>Daoud, J.</creatorcontrib><creatorcontrib>Errihani, H.</creatorcontrib><creatorcontrib>Essoudaigui, F.</creatorcontrib><creatorcontrib>Gachi, F.</creatorcontrib><creatorcontrib>Harif, M.</creatorcontrib><creatorcontrib>Hilmani, S.</creatorcontrib><creatorcontrib>Hsissen, L.</creatorcontrib><creatorcontrib>Idali, B.</creatorcontrib><creatorcontrib>Karkouri, M.</creatorcontrib><creatorcontrib>Kerboua, E.</creatorcontrib><creatorcontrib>Ouahabi, A.</creatorcontrib><creatorcontrib>Sahraoui, S.</creatorcontrib><creatorcontrib>Sadki, O.</creatorcontrib><creatorcontrib>Sami, A.</creatorcontrib><creatorcontrib>Samlali, R</creatorcontrib><creatorcontrib>Terkmani, F.</creatorcontrib><creatorcontrib>French Panel by alphabetic order</creatorcontrib><creatorcontrib>North Africa Panel by alphabetic order</creatorcontrib><creatorcontrib>North Africa Panel</creatorcontrib><creatorcontrib>French Panel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical reviews in oncology/hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Belkacemi, Y.</au><au>Bolle, S.</au><au>Bourdeaut, F.</au><au>Collin, P.</au><au>Cornu, P.</au><au>Delatre, J.-Y.</au><au>Dhermain, F.</au><au>Doz, F.</au><au>Habrand, J.-L.</au><au>Hoang-Xuan, K.</au><au>Idbaih, A.</au><au>Mammar, H.</au><au>Martin-Duverneuil, N.</au><au>Mokhtari, K.</au><au>Roujeau, T.</au><au>Acharqui, A.</au><au>Atit Benali, S.</au><au>Bakhti, S.</au><au>Bena, F.</au><au>Bendjaafar, N.</au><au>Benider, A.</au><au>Bouaouina, N.</au><au>Bounedjar, A.</au><au>Boussen, H.</au><au>Bouyoucef, K.</au><au>Bouzid, K.</au><au>Chougai, Z.</au><au>Daoud, J.</au><au>Errihani, H.</au><au>Essoudaigui, F.</au><au>Gachi, F.</au><au>Harif, M.</au><au>Hilmani, S.</au><au>Hsissen, L.</au><au>Idali, B.</au><au>Karkouri, M.</au><au>Kerboua, E.</au><au>Ouahabi, A.</au><au>Sahraoui, S.</au><au>Sadki, O.</au><au>Sami, A.</au><au>Samlali, R</au><au>Terkmani, F.</au><aucorp>French Panel by alphabetic order</aucorp><aucorp>North Africa Panel by alphabetic order</aucorp><aucorp>North Africa Panel</aucorp><aucorp>French Panel</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Guidelines, “minimal requirements” and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working party</atitle><jtitle>Critical reviews in oncology/hematology</jtitle><addtitle>Crit Rev Oncol Hematol</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>98</volume><spage>189</spage><epage>199</epage><pages>189-199</pages><issn>1040-8428</issn><eissn>1879-0461</eissn><abstract>Abstract Glioblastoma is the most common and the most lethal primary brain tumor in adults. Although studies are ongoing, the epidemiology of glioblastoma in North Africa ( i.e. Morocco, Algeria and Tunisia) remains imperfectly settled and needs to be specified for a better optimization of the neuro-oncology healthcare across the Mediterranean area and in North Africa countries. Over the last years significant therapeutic advances have been accomplished improving survival and quality of life of glioblastoma patients. Indeed, concurrent temozolomide-radiotherapy (temoradiation) and adjuvant temozolomide has been established as the standard of care associated with a survival benefit and a better outcome. Therefore, considering this validated strategy and regarding the means and some other North Africa countries specificities, we decided, under the auspices of AROME (association of radiotherapy and oncology of the Mediterranean area; www.aromecancer.org ), a non-profit organization, to organize a dedicated meeting to discuss the standards and elaborate a consensus on the “minimal requirements” adapted to the local resources. Thus, panels of physicians involved in daily multidisciplinary brain tumors management in the two borders of the Mediterranean area have been invited to the AROME neuro-oncology working party. We report here the consensus, established for minimal human and material resources for glioblastoma diagnosis and treatment faced to the standard of care, which should be reached. If the minimal requirements are not reached, the patients should be referred to the closest specialized medical center where at least minimal requirements, or, ideally, the standard of care should be guaranteed to the patients.</abstract><cop>Netherlands</cop><pub>Elsevier Ireland Ltd</pub><pmid>26626226</pmid><doi>10.1016/j.critrevonc.2015.10.014</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1040-8428
ispartof Critical reviews in oncology/hematology, 2016-02, Vol.98, p.189-199
issn 1040-8428
1879-0461
language eng
recordid cdi_proquest_miscellaneous_1760924434
source ScienceDirect Freedom Collection 2022-2024
subjects Adult
Africa, Northern
AROME
Brain Neoplasms - pathology
Brain Neoplasms - therapy
Brain tumors
Dacarbazine - analogs & derivatives
Glioblastoma
Glioblastoma - pathology
Glioblastoma - therapy
Guidelines for practice
Hematology, Oncology and Palliative Medicine
Humans
Medical Oncology - organization & administration
Medical Oncology - standards
Mediterranean Region
Neurology - organization & administration
Neurology - standards
Practice Guidelines as Topic
Quality of Life
Radiotherapy
Radiotherapy - standards
Societies, Medical - organization & administration
Societies, Medical - standards
Standard of Care
Temozolomide
title Guidelines, “minimal requirements” and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working party
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T13%3A48%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Guidelines,%20%E2%80%9Cminimal%20requirements%E2%80%9D%20and%20standard%20of%20care%20in%20glioblastoma%20around%20the%20Mediterranean%20Area:%20A%20report%20from%20the%20AROME%20(Association%20of%20Radiotherapy%20and%20Oncology%20of%20the%20Mediterranean%20arEa)%20Neuro-Oncology%20working%20party&rft.jtitle=Critical%20reviews%20in%20oncology/hematology&rft.au=Belkacemi,%20Y.&rft.aucorp=French%20Panel%20by%20alphabetic%20order&rft.date=2016-02-01&rft.volume=98&rft.spage=189&rft.epage=199&rft.pages=189-199&rft.issn=1040-8428&rft.eissn=1879-0461&rft_id=info:doi/10.1016/j.critrevonc.2015.10.014&rft_dat=%3Cproquest_cross%3E1760924434%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c499t-3fb24d3333df976ab90a53e568c0660fe6df0b05255065c27aab2d3b7be4c8af3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1760924434&rft_id=info:pmid/26626226&rfr_iscdi=true